Global Pharmacy Market to Reach USD 4.1 Trillion by 2035, Growing at 5% CAGR | CVS Health, Walgreens Boots Alliance, Walmart

The global pharmacy market, valued at USD 2.5 trillion in 2025, will reach USD 2.6 trillion in 2026 and expand to USD 4.1 trillion by 2035, advancing at a compound annual growth rate (CAGR) of 5% over the forecast period. A surging burden of chronic diseases, rapid adoption of e-pharmacy platforms, and the integration of digital health services across community pharmacy chains are collectively reshaping where and how patients access medicines worldwide.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/pharmacy-market/request-sample.html

MARKET OVERVIEW
The pharmacy market encompasses the full commercial chain through which prescription drugs, over-the-counter (OTC) medications, medical devices, and ancillary health and wellness products reach patients. The industry spans retail pharmacy chains, hospital pharmacies, specialty pharmacies, and a rapidly expanding e-pharmacy channel, all of which are simultaneously competing and converging as patient expectations shift toward convenience-first care delivery.
The scale of the problem these pharmacies address is substantial. According to the U.S. Department of Health, approximately 133 million Americans live with at least one chronic disease, and that figure does not account for the additional demand from aging populations across Europe and Asia-Pacific. Pharmacies have responded by broadening their footprint well beyond dispensing counters. Many chains now function as comprehensive health hubs offering glucose monitoring, cholesterol screening, immunizations, and specialty drug counseling. In July 2024, Babson Diagnostics launched blood testing services through two retail pharmacy locations in Texas, a move that illustrates exactly how community pharmacies are taking on expanded clinical roles that were once the exclusive domain of hospital outpatient departments.

On the digital front, Amazon Pharmacy announced plans in October 2024 to open facilities in 20 U.S. cities by 2025, enabling same-day prescription delivery. Meanwhile, funding continues to flow into e-pharmacy startups: Alto Pharmacy secured USD 120 million in September 2023, PharmEasy raised USD 216 million in April 2024, and India-based MrMed attracted USD 500,000 in August 2023 for regional expansion. These investments signal that institutional confidence in the online pharmacy model is not slowing down.

KEY GROWTH DRIVERS
Rising Chronic Disease Prevalence Sustains Prescription Volume More than 35% of total drug spending globally flows toward specialty brand drugs for conditions such as cancer, type 2 diabetes, and congestive heart failure. As incidence rates for these diseases rise, particularly in low- and middle-income countries where cancer incidence is projected to climb by 142% and 99%, respectively, the volume of prescriptions that move through both physical and digital pharmacy channels will only increase.

E-Pharmacy Adoption Accelerates Across All Major Markets Consumer migration from offline to online pharmacy purchasing has accelerated measurably over the past three years. In the U.S., surveys show a 10% rise in the share of Americans buying medications through online channels. The e-pharmacy segment carries the highest growth rate within the broader market, posting a projected CAGR of 6.3% through 2035. Platform operators, from pure-play apps to vertically integrated retailers like Amazon, are competing for this volume with aggressive same-day and next-day delivery commitments.

Specialty Medicines and Biologics Expand the Revenue Base Demand for biologics is growing faster than the broader drugs market, and generic drugs are also gaining share at the expense of branded products as patent cliffs accelerate. Johnson & Johnson's September 2024 agreement with specialty pharmacy Onco360 for the distribution of its non-small cell lung cancer therapy LAZCLUZE is representative of a broader trend: manufacturers routing complex therapies through specialty pharmacy networks to ensure appropriate dispensing and patient support.

Loyalty Programs and Customer-Centric Services Drive Retention Pharmacy chains are investing heavily in loyalty infrastructure. In the U.S., 33% of consumers enrolled in new pharmacy loyalty programs in 2022, while 57% of global consumers used loyalty points that year to reduce their out-of-pocket medication costs. Personalized offers, valued by 60% of consumers surveyed, are becoming a meaningful competitive differentiator, especially as retail pharmacies face pricing pressure from both online players and pharmacy benefit managers.

Digitalization and Automation Improve Margin and Safety Micro-fulfillment centers, automated dispensing systems, and e-prescribing integration are reducing dispensing errors while cutting operational costs. These technology investments are not just defensive; they are expanding service capacity and allowing pharmacists to redirect time toward clinical consultations, a key differentiator that brick-and-mortar chains actively emphasize over online-only competitors.

MARKET SEGMENTATION
By type of pharmacy, retail pharmacy currently holds close to 50% of market share and will remain the dominant channel through 2035, supported by its accessibility advantages for patients managing chronic conditions, as well as its expanding specialty and mail-order capabilities. CVS Health and Walgreens Boots Alliance lead this segment in the U.S. The e-pharmacy channel, while smaller in absolute terms, is the fastest-growing segment within the pharmacy market, advancing at a CAGR of 6.3%. Within e-pharmacy, app-based platforms currently command the largest share, though web-based platforms are closing the gap given their lower friction for first-time users.

By product type, drugs and pharmaceuticals account for the largest revenue share across all pharmacy formats. Within this category, branded and patented drugs currently lead, but generic drugs are closing at a notably higher CAGR as patent expirations multiply. Small molecules dominate by volume, while biologics represent the faster-growing molecule type. By therapeutic area, oncological disorders hold the top position among all disease categories, a reflection of the escalating global cancer burden and the high per-prescription cost of oncology drugs.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/pharmacy-market/request-quote.html

REGIONAL INSIGHTS
North America commands approximately 42% of the global pharmacy market and will maintain that position through the forecast period. The U.S. drives this dominance through its high per-capita drug expenditure, mature retail pharmacy infrastructure, and a fast-growing online pharmacy channel that has attracted investment from major technology and consumer companies. The rising burden of chronic diseases among the U.S. population sustains consistent prescription volumes, and the market's receptiveness to value-added services, specialty pharmacy, mail order, and clinical testing, keeps average revenue per pharmacy visit on an upward trajectory.

Asia-Pacific represents the most dynamic growth opportunity among all regions, with a projected CAGR of 5.6% through 2035, outpacing the global average. Population growth, rising disposable incomes, improving healthcare access in rural areas through telehealth infrastructure, and a surge in e-pharmacy funding across markets like India are all accelerating this trajectory. Europe holds the second-largest share globally. Germany's online pharmacy sector is expanding, with Apo.com Group reporting 30% revenue growth in the first half of 2023. In the U.K., the closure of 436 retail pharmacies in 2023, as documented by Healthwatch England, is creating an opening for supermarket-integrated online pharmacies, with ASDA entering the space in April 2024.

COMPETITIVE LANDSCAPE
The global pharmacy market includes Ahold Delhaize, Albertsons, A.S. Watson, Bestway, Cardinal Health, Cigna (Express Scripts), COSMOS, Costco, CVS Health, Dirk Rossmann, Dr. Max, Good Neighbor Pharmacy, Health Mart, Kroger, Matsumoto Kiyoshi, Phoenix, Rite Aid, The Jean Coutu, Walmart, Walgreens Boots Alliance, and Well Pharmacy.

The market is bifurcating. Established retail chains are investing in clinical service expansion, loyalty programs, and specialty pharmacy capabilities to protect their volumes against digital encroachment. Meanwhile, pure-play e-pharmacy operators are using venture funding and technology to compete on convenience and price. The primary battleground is patient stickiness: chains like Walgreens emphasize the irreplaceable value of in-person pharmacist interaction across 8,600 U.S. locations, while digital entrants respond with same-day delivery and app-based medication management. Strategic acquisitions are also reshaping the mid-tier, as seen in Elevance Health's CarelonRx purchasing Kroger's specialty pharmacy business in March 2024 and COSMOS completing its acquisition of Pelofarm's distribution network in June 2024.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/pharmacy-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.